HTG Molecular Diagnostics (NASDAQ:HTGM) has been assigned a $6.00 price objective by equities researchers at HC Wainwright in a report issued on Friday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 72.91% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on HTGM. ValuEngine cut shares of HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 10th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $4.88.

Shares of HTG Molecular Diagnostics (HTGM) traded down $0.56 during mid-day trading on Friday, reaching $3.47. 6,626,850 shares of the company’s stock were exchanged, compared to its average volume of 5,028,725. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25. The company has a market cap of $39.73 and a PE ratio of -1.36.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. raised its holdings in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,234 shares of the medical research company’s stock after acquiring an additional 37,841 shares during the quarter. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.15% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/05/hc-wainwright-reiterates-6-00-price-target-for-htg-molecular-diagnostics-htgm-2.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.